JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schuette, S. A.
Right arrow Articles by Morris, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schuette, S. A.
Right arrow Articles by Morris, S. J.
Journal of the American College of Nutrition, Vol. 22, No. 5, 379-387 (2003)
Published by the American College of Nutrition

Original Research

Dysprosium Chloride as a Nonabsorbable Gastrointestinal Marker for Studies of Stable Isotope-Labeled Triglyceride Excretion in Man

Sally A. Schuette, PhD, Morteza Janghorbani, PhD, Mitchell B. Cohen, MD, Susan Krug, MS, RD, Terri Schindler, RD, LD, David A. Wagner, PhD and Steven J. Morris, PhD

BioChemAnalysis Corp (S.A.S., M.J.)
Center for Stable Isotope Research Inc (M.J.), Chicago, Illinois
Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio (M.B.C., S.K., T.S.)
Metabolic Solutions Inc., Nashua, New Hampshire (D.A.W.)
University of Missouri, Columbia, Missouri (S.J.M.)

Address correspondence to: M Janghorbani, BioChemAnalysis Corp., 2201 W Campbell Park Dr, Chicago, IL 60612-3501. mjanghor{at}hotmail.com

Objective: The aim of this work was to determine if dysprosium chloride (DyCl3) is a suitable nonabsorbable marker for studies of labeled-triglyceride excretion in cystic fibrosis patients allowing excretion to be determined accurately after analysis of one or two stools.

Methods: A series of 66 absorption studies were conducted in 36 young cystic fibrosis patients over a five year period. All tests consisted of ingesting a single test meal containing both 13C-labeled triglyceride (TG*) and DyCl3; in most studies the food colorant brilliant blue (FD&C blue #1) was administered along with the DyCl3. Ingestion of the test meal was followed by collection of individual stools for 72 to 96 hours. Stools were analyzed for 13C-Excess (13C*) and Dy.

Results: Excretion of Dy in cystic fibrosis patients who exhibited a wide-range of steatorrhea was quantitative. Fractional excretion of Dy and 13C* in individual stools showed a high linear correlation (r2 = 0.969) with a slope and y-intercept close to unity and zero, respectively. As a result, estimates of TG* excretion based on analysis of only two stools (partial pool method, PPM) were not different from those based on the analysis of all stools or stool composites. This was true both when Dy content and when stool color due to ingested brilliant blue was used to determine which stools to analyze for the PPM.

Conclusions: Combining the use of Dy and brilliant blue permits reasonably accurate estimates of fecal TG* excretion after analysis of samples from two easily identified stools. This practical method can be used to address many important clinical and experimental questions regarding triglyceride digestion and absorption that may otherwise go unanswered.

Key words: 13C-label, cystic fibrosis, malabsorption, nonabsorbable marker, triglycerides

Abbreviations: Dy = dysprosium • 13C* = 13C-Excess • TG* = 13C-labeled triglyceride • P*P*P* = TRIPALMITIN-1,1,1-13C3 • PP*P = TRIPALMITIN-2-palmitoyl-1,2-13C2 • P*LP* = 2-LAURYL-1,3-DIPALMITIN-dipalmitoyl-1,1,2,2-13C4 • P*MP* = 2-MYRISTYL-1,3-DIPALMITIN-dipalmitoyl-1,1,2,2-13C4 • TPM = total pool method • PPM = partial pool method






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Nutrition.